US 12,297,220 B2
Phenethylamines and cathinones precursors
Bernard Cote, Notre-Dame-de-l'lle-Perrot (CA); Jennifer Schmidt, Garden City, NY (US); and Martin Stogniew, Lakewood Ranch, FL (US)
Assigned to TRANSCEND THERAPEUTICS, INC., New York, NY (US)
Filed by Transcend Therapeutics, Inc., New York, NY (US)
Filed on Nov. 21, 2024, as Appl. No. 18/955,261.
Application 18/955,261 is a continuation of application No. PCT/US2023/030140, filed on Aug. 14, 2023.
Claims priority of provisional application 63/471,369, filed on Jun. 6, 2023.
Claims priority of provisional application 63/398,703, filed on Aug. 17, 2022.
Prior Publication US 2025/0129108 A1, Apr. 24, 2025
Int. Cl. C07F 9/655 (2006.01); A61K 9/00 (2006.01); A61K 31/665 (2006.01); C07D 317/48 (2006.01)
CPC C07F 9/65517 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/665 (2013.01); C07D 317/48 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A compound of Formula (III):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
X is independently selected from the group consisting of:
(a) —C(O)OCH(R4)OP(O)OR11(OR12),
(b) —CH2OC(O)R3, and
(c) —C(O)(CH2)nZaR5;
wherein:
n is 3 or 4;
R1 and R2 are each independently —C1-6alkyl or —C3-6cycloalkyl;
R3 is selected from the group consisting of: —C1-6alkyl, C3-6cycloalkyl, —C1-6haloalkyl, aryl, and heteroaryl;
R4 is H, —C1-6alkyl or C3-6cycloalkyl;
R5 is selected from the group consisting of: —C(O)R3, —C(O)OR3, —P(O)OR11(OR12), an amino acid, and a peptide;
Za is O or NR4;
R11 and R12 are each independently H, —C1-6alkyl, —C1-6heteroalkyl, —C3-6cycloalkyl, —C1-6haloalkyl, aryl or heteroaryl, wherein —C1-6alkyl, —C1-6heteroalkyl, —C3-6cycloalkyl, —C1-6haloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more —C1-6alkyl, —C1-6heteroalkyl, —C3-6cycloalkyl, —C1-6haloalkyl, aryl or heteroaryl.